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Abstract: Primary hypothyroidism is the most common endocrine disease. Although 
the diagnosis and treatment of hypothyroidism is often considered simple, there are large 
numbers of people with this condition who are suboptimally treated. Even in those people 
with hypothyroidism who are biochemically euthyroid on levothyroxine replacement there is a 
significant proportion who report poorer quality of life. This review explores the historical and 
current treatment options for hypothyroidism, reasons for and potential solutions to suboptimal 
treatment, and future possibilities in the treatment of hypothyroidism.
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Introduction
Primary hypothyroidism or thyroid hormone deficiency due to abnormality in the 
thyroid gland is the most common endocrine disease. The prevalence of hypothyroidism 
in the general population ranges from 3.8%–4.6%.1–4 The Whickham survey showed 
an annual incidence of hypothyroidism of 4.1 per 1000 in women and 0.6 per 1000 in 
men.2 Furthermore, a more recent study from the UK suggests that the incidence 
of hypothyroidism is rising,3 although there appears to be geographical variation. 
For example, epidemiological studies suggest Denmark has nine times fewer new 
cases of hypothyroidism than the UK.5 In the UK, over 23 million prescriptions for 
levothyroxine were written in 2010, making it the third most prescribed medication 
after simvastatin and aspirin.6
Diagnosis and treatment of hypothyroidism is often considered simple and is mostly 
carried out in a primary care setting. However, studies continue to show problems in 
the management of this condition. Many patients on thyroid hormone replacement are 
either under-replaced or over-replaced7–10 and a significant number of patients on thyroid 
hormone replacement report not feeling well despite having thyroid function tests within 
the healthy reference range.11 In this review, we discuss current approaches to the 
management of primary hypothyroidism and explore potential future developments.
Causes of primary hypothyroidism
In Western countries, the most common cause of primary hypothyroidism is autoimmune 
thyroiditis. However, in many parts of the world, iodine deficiency remains an important 
cause. Other common causes of hypothyroidism include thyroidectomy, radioiodine 
therapy, and drugs such as amiodarone, lithium, thionamide, iodine,   interferon, 
  sunitinib, rifampicin, and   thalidomide. Transient hypothyroidism may occur in 
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subacute (de Quervain’s) thyroiditis and also in postpartum 
thyroiditis. In both of these conditions 75%–85% of patients 
regain normal thyroid function.12 Congenital hypothyroidism, 
due to   thyroid gland agenesis or dyshormonogenesis, affects 
about one in 4000 newborns and is the commonest congenital 
endocrinopathy.13
Diagnosis of primary 
hypothyroidism
The common clinical features associated with hypothyroid-
ism are tiredness, weight gain, dry skin, cold intolerance, 
constipation, muscle weakness, puffiness around the eyes, 
hoarse voice, and poor memory. However, a study surveying 
thyroid disease in Colorado has shown that the sensitivity of 
individual symptoms ranges from 2.9% to 24.5%.7 Although 
the likelihood of hypothyroidism increases with increasing 
numbers of symptoms,7,14 absence of symptoms does not 
exclude the diagnosis. Furthermore, these symptoms are non-
specific and common in the euthyroid population with around 
20% of euthyroid subjects having four or more hypothyroid 
symptoms.7 Therefore, the diagnosis of hypothyroidism must 
be made biochemically.
Overt primary hypothyroidism is diagnosed biochemically 
with a serum thyroid stimulating hormone (TSH) concentra-
tion above the reference range and low free T4. If the TSH is 
raised but free T4 is in the normal range then this is referred 
to as subclinical hypothyroidism. The population reference 
range of TSH is around 0.4–4.5 mIU/L and most patients with 
overt hypothyroidism have TSH above 10 mIU/L. However, 
several controversies surrounding the TSH reference range 
have surfaced in recent years. Firstly, because the TSH in the 
general population is not normally distributed, and more than 
95% of healthy individuals have TSH less than 2.5 mIU/L, 
it has been suggested that the upper limit of the TSH refer-
ence range may be skewed by occult thyroid dysfunction,15 
leading to a debate whether the upper limit of the TSH ref-
erence range should be   lowered from 4.5 to 2.5 mIU/L.16–18 
Secondly, in pregnancy, it is now recognized that trimester-
specific reference ranges for TSH should be used to assess 
thyroid function; when trimester-specific reference ranges 
are not available, TSH of 2.5 mIU/L in the first trimester and 
3 mIU/L in the later trimesters are considered as the upper 
limits of the   reference range.19,20 Thirdly, because the TSH 
distribution and   reference   limits are influenced by age and 
ethnicity, the use of age and race-standardized TSH reference 
ranges has also been   suggested.21 Finally, it has been shown 
that variation of TSH within an individual is narrower than 
the variation in the general population, supporting the con-
cept of an individual reference range, such that a TSH level 
within the population reference range may still be abnormal 
for the individual.22 It is thought that genetic factors play a 
part in influencing the thyroid set-point in the individual. 
This is supported by studies showing associations between 
TSH and common variations in different genes, including 
PDE8B and TSHR,23–26 and a study showing that a common 
variation in the PDE8B gene influences TSH reference ranges 
in pregnant women.27
Treatment of primary 
hypothyroidism
Historical perspective
By the end of the 19th century, myxedema had been attributed 
to diminished thyroid function and a cretinism-like condition 
(also described as cachexia strumipriva) had been observed 
following thyroidectomy in animals and humans.28 Moreover, 
xenotransplantation of animal thyroid gland had been shown 
to improve symptoms in women suffering from myxedema 
temporarily. In 1891, Murray described the first regime of thy-
roid hormone replacement, subcutaneously injecting extract 
of sheep thyroid into a patient with   hypothyroidism.29 It was 
soon shown that oral administration of thyroid extract was 
as effective.30 In 1914, Kendall purified thyroxine crystals, 
which became commercially available. Harrington identified 
the structure of thyroxine in 1926 and synthetic thyroxine 
was available for clinical use by the 1930s. However, it 
took many more years before thyroxine became preferable 
to desiccated thyroid extract as the treatment of choice for 
hypothyroidism.28 In 1952, Gross and Pitts-River identified 
the more potent liothyronine.31
Dosage of levothyroxine
Levothyroxine is the treatment of choice for hypothyroidism. 
It has a 7 day half-life, allowing daily dosing.12 A randomized 
controlled trial has shown that, in patients with no significant 
comorbidities, initiation of levothyroxine at a full dose based 
on body weight (1.6 µg/kg/day) is safe, effective, and requires 
fewer resources than using a more traditional approach of 
starting with a small dose and gradually titrating upward.32 
The exceptions to this are the elderly and patients with known 
ischemic heart disease (see the “Levothyroxine replacement 
in special circumstances” section of this review).
Timing of levothyroxine
Conventionally, hypothyroid patients are advised to take 
levothyroxine on an empty stomach half an hour before 
breakfast to prevent impairment of absorption by food. Several 
recent studies have looked at whether a bedtime dosage of 
levothyroxine is preferable. A small nonrandomized study 
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involving eleven hypothyroid patients on a stable dose of 
morning levothyroxine found a decrease in mean TSH and 
an increase in free thyroid hormone levels when the timing 
of levothyroxine dosage was changed to bedtime.33 The 
same investigators, in a subsequent randomized double-blind 
crossover trial of 105 consecutive patients, have reaffirmed that 
biochemical control was best achieved by night-time dosing. 
Taking levothyroxine at bedtime resulted in a decrease in mean 
TSH of 1.25 mIU/L (95% confidence interval [CI] 0.60–1.89), 
and an increase in free T4 of 0.07 ng/dL (95% CI 0.02–0.13) 
and total T3 of 6.5 ng/dL (95% CI 0.9–12.1).34 However, 
there were no improvements in quality of life scores, blood 
pressure, or lipid profile. A retrospective study of 15 elderly 
patients in a nursing home showed a nonsignificant decrease in 
mean TSH of 0.29 mIU/L when the time of administration of 
levothyroxine was changed from early morning to midnight.35 
In contrast, a randomized crossover trial in the US compared 
taking levothyroxine in the fasting state, with breakfast, or at 
bedtime in 65 patients with primary hypothyroidism and thyroid 
cancer, and found that TSH levels were significantly lower and 
less variable when levothyroxine was taken in the fasting state 
than at other times.36 Furthermore, Rajput et al randomized 
77 patients with newly diagnosed autoimmune hypothyroidism 
to taking their levothyroxine half an hour before breakfast or 
two hours after their evening meal, and found no difference 
in TSH, lipid profile, clinical symptoms, quality of life scores, 
or the dose required to achieve euthyroidism between the two 
groups.37 The conflicting findings of different studies may 
reflect heterogeneity in the conditions of patients studied (for 
example, newly diagnosed patients versus patients on a stable 
dose of levothyroxine, and patients with thyroid cancer versus 
patients with autoimmune hypothyroidism) as well as in eating 
habits in relation to bedtime in the different study populations. 
Nevertheless, these studies suggest that bedtime dosing of 
levothyroxine could be tried as an alternative strategy in those 
patients who have problems in taking morning levothyroxine 
on an empty stomach.
Monitoring thyroid function during 
levothyroxine replacement
When initiating levothyroxine therapy, serum TSH should 
be measured to monitor for adequate replacement. TSH can 
take up to 4 months to normalize, even when starting on a 
full dose replacement regimen, due to thyrotroph hyperplasia. 
It is recommended that the TSH is measured 6–8 weeks 
after initiation of, or a change in levothyroxine dose. Once 
the patient is on a stable dose of levothyroxine, annual 
monitoring of TSH is recommended, although a retrospective 
study suggests that the monitoring interval could be safely 
increased to 18 months.38 Common causes of persistently 
elevated TSH in patients on levothyroxine replacement are 
shown in Table 1.
It is generally recommended to aim for a TSH in the 
lower half of the normal range, ie, typically ,2.5 mIU/L 
in patients with primary hypothyroidism on levothyroxine 
replacement.12,39 In a small study of 21 patients with primary 
hypothyroidism, titrating the dose of levothyroxine until the 
TSH was at the lower end of reference range or suppressed 
below the reference range was found to be associated 
with improved wellbeing in some patients.40 However, this 
observation was not confirmed by a double-blind random-
ized crossover trial, which has shown that small changes in 
levothyroxine dose to achieve a lower TSH do not result in 
an improved quality of life score.41 Furthermore, in a recent 
prospective study of 42 patients initiating levothyroxine 
treatment for newly diagnosed primary hypothyroidism, 
there was no difference in lipid profile, body composition, 
or bone mineral density in patients maintained on low TSH 
(0.4–2.0 mIU/L) as compared with those maintained on 
higher TSH (2–4 mIU/L) for 12 months, although resting 
energy expenditure was higher in patients maintained on 
the lower TSH target.42 Finally, overtreatment with levothy-
roxine leading to a suppressed TSH of below 0.1 mIU/L has 
been shown to be associated with adverse skeletal health, 
particularly in the elderly (see below). Taken together, 
these observations suggest that the target TSH level for 
most nonpregnant patients with primary hypothyroidism on 
levothyroxine replacement should be the population refer-
ence range and one should not necessarily increase the dose 
of levothyroxine in asymptomatic people with a TSH in the 
upper half of the normal range.
Drug interactions with levothyroxine
Several medications, supplements, and food can interfere 
with the absorption and action of levothyroxine (Table 2). 
Common drugs that can affect levothyroxine absorption 
Table  1  Causes  of  persistently  elevated  thyroid-stimulating 
hormone in a patient on levothyroxine replacement
• Inadequate levothyroxine dose
•   Poor compliance with medication (biochemistry usually showing high 
thyroid-stimulating hormone with normal free T4)
• Interaction with concomitant drugs (see Table 2)
• Taking levothyroxine with food
• Malabsorption
• Coexisting celiac disease or autoimmune gastritis
• Interference with the laboratory assay due to heterophil antibodies
• Coexisting thyroid hormone resistance (rare)
Abbreviation: T4, thyroxine
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include iron, calcium, cholestyramine, and aluminum and 
levothyroxine must be taken at least 4 hours apart from these 
drugs. Enzyme inducers, such as phenytoin, carbamazepine, 
phenobarbital, and rifampicin can increase the clearance of 
levothyroxine, necessitating an increased dose. Of women 
starting estrogen hormone replacement treatment, 35% were 
shown to need an increase in levothyroxine dose, thought 
to be due to increased thyroxine-binding globulin.43 It is 
noteworthy that hypothyroidism itself can lead to altered 
metabolism of medications, such that when rendered euthy-
roid, patients with hypothyroidism may need alterations in 
the dose of their medications. For example, initiation of 
levothyroxine in a hypothyroid patient may enhance the effect 
of warfarin, which may need dose adjustment.
Triiodothyronine-levothyroxine 
combination therapy
A significant minority of hypothyroid patients treated with 
levothyroxine do not feel completely well and have a poorer 
quality of life.11 There are several possible causes for impaired 
wellbeing in these patients. Firstly, a number of them have a 
TSH outside the normal range, suggesting a   suboptimal dosage 
of levothyroxine. Secondly, given that both hypothyroidism 
and dysphoria are common diagnoses, there will be a clini-
cal overlap and thus symptoms   attributed to hypothyroidism 
may not improve with treatment. Moreover, patients feeling 
unwell are more likely to seek medical advice and thus get their 
thyroid function tested. Thirdly, decreased wellbeing could 
be due to intrinsic autoimmunity   irrespective of the patient’s 
thyroid status.44 Lastly, serum TSH may not accurately reflect 
thyroid hormone concentrations in all target tissues.45 In a 
community-based survey, patients on levothyroxine, despite 
having normal TSH, were found to have significantly reduced 
psychological wellbeing as compared with age-matched and 
gender-matched controls.11 Likewise, a cohort study showed 
poorer quality of life and decreased neurocognitive functioning 
in 141 hypothyroid patients on adequate doses of levothyrox-
ine as compared with the general population.46 Indeed, many 
patients on levothyroxine do not achieve a physiological Free 
T3/Free T4 (FT3/FT4) ratio despite serum TSH being within 
the reference range,47,48 suggesting that hepatic and renal 
conversion of thyroxine to triiodothyronine may be impaired 
in these patients and this may account for the persistence of 
their symptoms. Furthermore, in thyroidectomized rats, tissue 
euthyroidism could be achieved by infusion of both levothy-
roxine and triiodothyronine and not by levothyroxine alone.49 
These observations led to the hypothesis that a triiodothyro-
nine-levothyroxine combination is necessary to restore tissue 
euthyroidism in patients with hypothyroidism.
Several studies have evaluated triiodothyronine-
  levothyroxine combination therapy in patients with 
  hypothyroidism. An early study from Lithuania showed sig-
nificant improvement in wellbeing when 50 µg of levothyrox-
ine was replaced with 12.5 µg of triiodothyronine;50 however, 
several subsequent randomized controlled trials have failed 
to confirm this effect. A meta-analysis of eleven randomized 
controlled trials involving 1216 patients concluded that a 
triiodothyronine-levothyroxine combination is not more 
effective than levothyroxine alone.51 Interestingly, patients 
in two trials reported a preference for combination therapy 
despite no objective improvement in wellbeing.52,53 A major 
limitation of these studies is that triiodothyronine in the 
current formulation does not result in a normal physiological 
profile and the triiodothyronine-levothyroxine combination 
has been shown to be associated with wide fluctuations in 
FT3 levels.54 Furthermore, it is possible that combination 
therapy is effective only in a subgroup of patients. This is 
supported by a recent study, which showed that a common 
genetic variation in the deiodinase type 2 (DIO2) gene 
Table 2 Substances that interact with levothyroxine
Drugs and supplements that decrease the effect  
of levothyroxine
Reduced levothyroxine absorption
  Iron 
  Calcium carbonate 
  Cholestyramine 
  Aluminum 
  Cimetidine 
  Sucralfate 
  Iodine (includes kelp tablets) 
  Selenium 
  Magnesium 
  Zinc 
  Soya 
  Fiber 
  Caffeine 
  Antacids
Increased levothyroxine clearance
  Phenytoin 
  Carbamazepine 
  Phenobarbital 
  Rifampicin
Increased levothyroxine binding
  Estrogen hormone replacement therapy
Drugs affected by levothyroxine
Drug effect enhanced by levothyroxine
  warfarin 
  Amitriptyline
Drug effect decreased by levothyroxine
  Propranolol
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is associated with worse baseline quality of life scores in 
hypothyroid patients on levothyroxine and greater response 
to the combination therapy.55
Desiccated pig thyroid extract
Desiccated pig thyroid extract (Armour® thyroid; Forest 
Pharmaceuticals, New York, NY) contains both thyroxine 
and triiodothyronine in a ratio of about 4:1. This is in contrast 
with human physiological thyroxine and triiodothyronine 
ratio of 14:1,56 and therefore the thyroid extract contains a 
supraphysiological amount of triiodothyronine. There is no 
clinical trial evidence to show that it is more effective than 
levothyroxine.
Triiodothyronine therapy
A recent randomized double-blind crossover trial has 
studied the effects of triiodothyronine versus levothyroxine 
in a cohort of 14 patients with primary hypothyroidism of 
various etiologies.57 Patients received triiodothyronine or 
levothyroxine three times a day to achieve a target TSH of 
0.5–1.5 mIU/L. After 6 weeks of treatment, triiodothyronine 
was associated with reduced body weight and an improved 
lipid profile and had no effect on cardiovascular function, 
insulin sensitivity, or quality of life scores. Further studies 
with bigger sample sizes and longer follow-up are necessary 
before this regime could be adopted to treat a subgroup of 
patients with hypothyroidism in routine clinical practice.
Levothyroxine replacement  
in special circumstances
Subclinical hypothyroidism
Although subclinical hypothyroidism is a biochemical 
diagnosis characterized by raised TSH with normal serum 
thyroid hormone levels, many patients have nonspecific 
symptoms. Subclinical hypothyroidism is common in the 
general population (with a prevalence of 4%–8%) and the 
prevalence increases with advancing age.1,7 It can progress 
to overt hypothyroidism; the 20-year follow-up study of the 
Whickham survey has shown that 4.3% people with raised 
TSH and positive thyroid antibodies and 3% with raised 
TSH without antibodies develop overt hypothyroidism 
annually.2 However, a prospective study has shown that, 
in about 5% of patients with subclinical hypothyroidism, 
TSH returns to normal after 1 year without any treatment.58 
Likewise, in another large study, 51% of 3775 patients 
with TSH 5.5–10 mIU/L were found to have TSH levels 
within the reference range when tested 5 years later.59 
Observational studies have shown inconsistent associations 
between subclinical hypothyroidism and hyperlipidemia, 
endothelial dysfunction, cardiovascular disease, and cognitive 
impairment.7,60–62 A recent meta-analysis of individual data 
for over 55,000 subjects from eleven studies showed that 
subclinical hypothyroidism is associated with an increased 
risk of cardiovascular events and mortality, particularly 
if TSH is 10 mIU/L or higher.61 Although randomized 
controlled trials have shown a trend towards improved lipid 
profile, endothelial function, and echocardiographic features 
with levothyroxine treatment in patients with subclinical 
hypothyroidism,63,64 there are no studies to show that 
levothyroxine reduces cardiovascular events or mortality. 
Furthermore, a recent randomized controlled trial showed 
no evidence of improvement of cognitive function with 
levothyroxine treatment in elderly patients with subclinical 
hypothyroidism.65
Routine use of levothyroxine in subclinical hypothyroid-
ism is controversial. An expert panel has supported the use 
of levothyroxine in patients with subclinical hypothyroid-
ism if TSH is higher than 10 mIU/L.66 Whilst subclinical 
hypothyroidism in pregnant women and women planning 
to conceive should also be treated with levothyroxine, great 
caution should be exercised when treating elderly patients 
with this condition (see below). In symptomatic patients 
with subclinical hypothyroidism and TSH below 10 mIU/L, 
a 3–6-month trial of levothyroxine is reasonable.39 In asymp-
tomatic patients with TSH less than 10 mIU/L, TSH should be 
monitored annually in the presence of thyroid antibodies and 
every 3 years if thyroid antibodies are absent.67 A pragmatic 
algorithm for the management of subclinical hypothyroidism 
is shown in Figure 1.
Pregnancy
Thyroid hormones are essential for the neurological 
development of the fetus.68 Because the fetal thyroid gland 
starts functioning only after 12–14 weeks of gestation, 
the fetus relies on maternal thyroid hormones for its early 
neurological development. Both overt and mild thyroid 
hormone insufficiency in pregnancy has been shown to be 
associated with impaired neuropsychological development 
of the offspring.68–71 Furthermore, maternal hypothyroidism 
is also associated with several other adverse obstetric out-
comes, including miscarriage, premature birth, gestational 
hypertension, and low birth weight72–75 and these adverse 
events may be prevented by optimum thyroid hormone 
replacement.76
Maternal hypothyroidism diagnosed in pregnancy 
should be corrected as soon as possible by initiating a full 
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replacement dose of levothyroxine (100–150 µg/day or 
2.0–2.4 µg/kg body weight/day).19 Most women with known 
hypothyroidism need a 30%–50% increase in the dose 
of levothyroxine during pregnancy77,78 and this increased 
dose requirement occurs as early as the first 4–6 weeks 
of   gestation.78 About a quarter of pregnant hypothyroid 
women on levothyroxine have high TSH, suggesting under-
  replacement at their first antenatal visit.79 This could, to 
some extent, be prevented by preconception optimization of 
levothyroxine dose80 and, for hypothyroid women planning 
pregnancy, levothyroxine dose ideally should be adjusted to 
keep TSH less than 2.5 mIU/L before   conception.19   Thyroid 
function should be checked as soon as the pregnancy is 
confirmed to adjust the dose of levothyroxine further. 
An   alternative approach is to advise the woman to increase 
the dose of levothyroxine by 30%–50%77 or by two tablets 
per week81 as soon as pregnancy is confirmed to avoid any 
delay in dose increment. Thyroid function should be moni-
tored at regular intervals (every 4–6 weeks) to adjust the 
dose of levothyroxine to keep TSH under 2.5 mIU/L in the 
first trimester and under 3.0 mIU/L in the second and third 
trimesters.19 Patients will need a reduction of their levothy-
roxine dose after pregnancy.
There is general consensus that subclinical hypothy-
roidism in pregnant women should also be treated with 
levothyroxine.19 However, whether all pregnant women 
should be screened for subclinical hypothyroidism remains 
controversial.19,79
Raised TSH
TSH > 10 mIU
+/− Low FT4
TSH 5–10 mIU
Low FT4
TSH 5–10 mIU
Normal FT4
Symptoms of
hypothyroidism
Yes
Yes
No
No
Positive Negative
3–6 months
trial of
thyroxine
Symptoms
resolved?
Treat with
thyroxine
lifelong
Consider
alternative
diagnoses
Recheck
TSH
annually
Recheck
TSH every
3 years
TPO
antibody
status
Figure 1 Algorithm for the pragmatic management of primary hypothyroidism. 
Note: Reproduced from British Medical Journal, Vaidya B, Pearce SH, 337, 284–289, 2008 with permission from BMJ Publishing Group Ltd.
Abbreviations: TSH, thyroid stimulating hormone; FT4, free thyroxine; TPO, thyroid peroxidase; mIU, milli-international unit.
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Elderly
The levothyroxine dose requirement gradually decreases 
with age,82,83 thought to be due to age-related decreases in 
  thyroxine degradation84 and in lean body mass.85   Furthermore, 
levothyroxine replacement may precipitate severe angina or 
myocardial infarction in an elderly person with asymptomatic 
ischemic heart disease. Therefore, in people over the age of 
65 years, levothyroxine should be started at a small dose (25–50 
µg/daily) and dose titration should be carried out slowly.
There is a high prevalence of suboptimal thyroid 
hormone replacement in the elderly. In a cross-sectional 
study involving elderly people aged 65 years or over on 
levothyroxine, 41% and 16% had suppressed and raised 
TSH suggestive of over-replacement and under-replacement, 
respectively.8 The risk of under-replacement of levothyroxine 
is less certain in this population, with studies showing an 
association between raised TSH and a lower mortality 
rate in the very elderly population.26,86,87 In contrast, the 
potential hazards of over-replacement of levothyroxine 
in the elderly population have been highlighted by the 
associations between suppressed TSH with reduced bone 
mineral density88,89 as well as increased risk of fractures.90 
In a recent large cohort study of elderly people above the 
age of 70 years, levothyroxine treatment has been found to 
be associated with an increased risk of fractures.91 Although 
thyroid function tests were not analyzed in this study, there 
was a correlation between the risk of fractures and the dose 
of levothyroxine, suggesting that the increased fracture risk 
may be related to over-replacement of levothyroxine. Several 
epidemiological studies have also shown an association 
between low or suppressed TSH and atrial fibrillation.92–95 
However, all of these studies, except the Framingham study,92 
have excluded patients on levothyroxine and, therefore, it 
remains unclear whether suppressed TSH due to exogenous 
levothyroxine is as deleterious to the heart as endogenous 
subclinical hyperthyroidism. Nevertheless, taken together, 
these observations underline the importance of careful 
monitoring and optimizing thyroid hormone replacement 
in the elderly with hypothyroidism.
Ischemic heart disease
Prolonged untreated hypothyroidism can lead to persistent 
bradycardia, an adverse atherogenic lipid profile, and 
deterioration in myocardial function. However, due to 
the positive inotropic and chronotropic effects of thyroid 
hormone on the heart, starting a full dose of levothyroxine 
could precipitate acute coronary syndrome in hypothyroid 
patients with previously silent coronary artery stenosis.96 
Therefore, newly diagnosed hypothyroid patients with 
ischemic heart disease should be started on a small dose 
of levothyroxine (12.5–25 µg/day) which is slowly up 
titrated every 4–6 weeks in increments of 12.5–25 µg/day 
until euthyroidism is achieved. Some patients may need to 
increase their antianginal medications to ensure full beta-
blockade, or undergo a coronary revascularization procedure 
to be able to tolerate an adequate dose of levothyroxine to 
achieve euthyroidism.97 The suggested starting dose regimes 
of levothyroxine for primary hypothyroidism in different 
situations are shown in Table 3.
Poor compliance
In a subset of hypothyroid patients in whom poor compliance 
with daily dosing of levothyroxine is suspected, a once-
weekly dosage of levothyroxine may be used as an alternative. 
In a randomized crossover trial involving 12 hypothyroid 
patients, once-weekly administration of seven times the 
normal daily dose of levothyroxine was shown to be effec-
tive and well tolerated.98 The study found a higher mean TSH 
level when patients were on a weekly regime compared with 
daily dosing, suggesting that a dose slightly higher than the 
calculated 7 day total may be needed to achieve optimum 
biochemical control on weekly regime. Because a high 
dose of levothyroxine may exacerbate angina or precipitate 
myocardial infarction, the weekly regime of levothyroxine 
is not appropriate for patients with ischemic heart disease. 
Furthermore, because the long-term adverse effects of a 
weekly levothyroxine regime are not known, it should be 
used only in exceptional cases of noncompliance after other 
approaches have failed.
Biochemically euthyroid patients  
with symptoms of hypothyroidism
Because symptoms of hypothyroidism are nonspecific, 
many patients have such symptoms without biochemical 
evidence of hypothyroidism. A randomized, double-blind, 
placebo-controlled, crossover trial involving 25 patients 
with symptoms of hypothyroidism but normal biochemistry 
showed no benefit from levothyroxine in improving wellbeing 
Table 3 Suggested starting dose of levothyroxine for primary 
hypothyroidism in different clinical situations
Normal otherwise well patients 1.6 µg/kg body weight/day
Pregnant patients 2.0–2.4 µg/kg body weight/day
Elderly patients 25–50 µg/day
Patients with ischemic heart disease 12.5–25 µg/day
Patients on enzyme-inducing drugs 2.0 µg/kg body weight/day
Abbreviations: µg, microgram; kg, kilogram.
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and cognitive function.99 Given that levothyroxine is an 
ineffective treatment and is associated with some adverse 
outcomes, it should not be used in these patients.
Future possibilities
After more than 120 years since Murray first successfully 
treated hypothyroidism with sheep thyroid extract29 and 
numerous subsequent advances in the field, there remain 
many uncertainties surrounding the management of this 
common disease. What is the target thyroid function for 
hypothyroid patients on levothyroxine replacement? What 
are the long-term outcomes of different target TSH levels 
on levothyroxine replacement? Should different age groups 
have different target TSH levels? Should individuals be 
assessed to determine their personal TSH reference range 
for future diagnosis and treatment of thyroid dysfunction? 
Does FT3/FT4 ratio provide additional information about 
tissue euthyroidism in patients on levothyroxine replacement? 
Furthermore, although there is increasing evidence from 
observational studies for an association between subclinical 
hypothyroidism and the risk of cardiovascular disease-related 
morbidity and mortality, randomized controlled trial evidence 
showing that levothyroxine treatment reduces the risk is still 
lacking. Interestingly, subclinical h  ypothyroidism can be 
viewed as an incipient autoimmune disease that develops 
into overt hypothyroidism over many years. Identification 
of biomarkers that are better than current thyroid antibody 
assays at predicting eventual hypothyroidism could lead 
to targeted intervention to prevent hypothyroidism. Oral 
  selenium supplementation appears to have efficacy in 
modifying the natural history of Graves’ orbitopathy,100 
and may prove to have immunomodulatory actions in other 
forms of autoimmune thyroid disease. In pregnancy, results 
of ongoing and future clinical trials are awaited to inform 
whether all pregnant women should be screened and treated 
for subclinical hypothyroidism.
It remains uncertain as to why a minority of   hypothyroid 
patients on levothyroxine continue to have residual   symptoms 
despite apparently adequate replacement, and it is hoped that 
future studies will clarify this enigma. Moreover, despite 
several randomized controlled trials showing a lack of benefit 
of combining triiodothyronine with levothyroxine in such 
patients,51 it is possible that triiodothyronine formulated to 
mimic the normal physiological profile may have a better 
outcome. Indeed, a proof of concept study has demonstrated 
the biochemical efficacy of a combination of long-acting 
triiodothyronine and levothyroxine on the T4/T3 ratio and 
TSH over levothyroxine monotherapy.101 Further studies are 
required to see whether this   biochemical   advantage translates 
into clinical benefit. Finally, recent genetic   studies have shown 
associations between common genetic variations and thyroid 
hormone levels,23–26,55,102 wellbeing in   levothyroxine-treated 
patients,55 and response to triiodothyronine-levothyroxine 
combination treatment,55 opening the door to the possibility 
of pharmacogenomics. Future genetic studies may help in 
identifying the subgroup of patients who would benefit from 
combination therapy.
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